The estimated Net Worth of Marc E Lippman is at least $37.3 Milhão dollars as of 3 November 2020. Marc Lippman owns over 142,090 units of Seagen Inc stock worth over $11,978,075 and over the last 22 years he sold SGEN stock worth over $24,911,985. In addition, he makes $427,604 as Independent Director at Seagen Inc.
Marc has made over 10 trades of the Seagen Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 142,090 units of SGEN stock worth $23,957,795 on 3 November 2020.
The largest trade he's ever made was selling 142,090 units of Seagen Inc stock on 3 November 2020 worth over $23,957,795. On average, Marc trades about 6,984 units every 83 days since 2003. As of 3 November 2020 he still owns at least 52,338 units of Seagen Inc stock.
You can see the complete history of Marc Lippman stock trades at the bottom of the page.
Dr. Marc E. Lippman, M.D. is Independent Director of Seattle Genetics, Inc., since June 2000. Since July 2018, Dr. Lippman has served as Professor of Oncology at Georgetown University Medical Center's Lombardi Comprehensive Cancer Center. From October 2017 to July 2018, Dr. Lippman served as the Kathleen and Stanley Glaser Professor of Medicine and Chairman of the Department of Medicine at the University of Miami Leonard M. Miller School of Medicine. From January 2008 to October 2017, Dr. Lippman served as the Deputy Director of the Sylvester Comprehensive Cancer Center of University of Miami Leonard M. Miller School of Medicine. Previously, from February 2001 to May 2007 he served as the John G. Searle Professor and Chairman of the Department of Internal Medicine at the University of Michigan School of Medicine. Previously, Dr. Lippman was the Director of the Lombardi Cancer Research Center from July 1988 to February 2001, Professor and Chairman of the Department of Oncology from July 1999 to February 2001 and Professor of Medicine at Georgetown University Medical School in Washington, D.C. from July 1988 to February 2001. He also served as Chief of the Division of Hematology-Oncology at Georgetown University Medical School from July 1995 to February 2001. He was Head of the Medical Breast Cancer Section of the Medicine Branch of the National Cancer Institute from July 1976 to July 1988. Dr. Lippman has authored over 500 peer-reviewed publications and one of the standard texts on breast cancer. He received a B.A., magna cum laude, from Cornell and an M.D. from Yale where he was elected to Alpha Omega Alpha. Dr. Lippman’s extensive experience in treating patients and conducting oncology research at the National Cancer Institute and at the medical schools of the University of Miami, the University of Michigan and Georgetown University provides an important patient perspective and focus on innovation in our development of antibody-based therapies.
As the Independent Director of Seagen Inc, the total compensation of Marc Lippman at Seagen Inc is $427,604. There are 17 executives at Seagen Inc getting paid more, with Clay Siegall having the highest compensation of $14,521,500.
Marc Lippman is 75, he's been the Independent Director of Seagen Inc since 2000. There are no older and 20 younger executives at Seagen Inc.
Over the last 22 years, insiders at Seagen Inc have traded over $729,924,224 worth of Seagen Inc stock and bought 35,347,908 units worth $1,433,871,526 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Felixbaker Julian Baker Bro..., eBrothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $18,157,295. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth $2,262,166.
seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys
Seagen Inc executives and other stock owners filed with the SEC include: